Ibrx stock forecast 2025 analysts tracking IBRX stock forecast

Analysts tracking IBRX stock forecast 2025 anticipate potential upside driven by clinical pipeline progress, with consensus estimates hovering around a possible $4.50–$6.00 range if trial outcomes remain favorable. Market sentiment is currently risk-on for biotech plays in niche immunotherapy. IBRX's accelerating position in the biotechnology industry is prominent and is deriving the right attention from analysts and investors. On January 10, Justin Zelin, an analyst at BTIG, initiated the stock with a buy rating and a price target of $6. The company's lead product Anktiva received approval following compelling response rates and durability results, explaining the thesis behind the rating. The analyst also believes that ImmunityBio's (NASDAQ:IBRX) partnership with the Serum Institute of India for the development of recombinant BCG is an impressive approach to its long-term supply chain management. The information and amounts presented above, including under the caption “Financial Overview,” reflects the Company’s preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its financial results or position as of June 30, 2025. Any actual amount that the Company reports in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be subject to its financial closing procedures and any final adjustments that may be made prior to the time its financial results for the period ended June 30, 2025 are finalized. As a result, these preliminary estimates may differ materially from the actual results that will be reflected in the Company’s condensed consolidated financial statements for the quarter when they are completed and publicly disclosed. Technical setups indicate possible consolidation before the next leg up. If accumulation continues, IBRX stock forecast 2025 suggests rally potential fueled by Q1–Q2 catalysts.